Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
Abstract Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as targeted therapies or more recently as immune checkpoint inhibitors (ICIs). The fact that only some patients benefit from these drugs poses the usual question in the field of onco‐hematology: that of the benef...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-04-01
|
| Series: | Pharmacology Research & Perspectives |
| Online Access: | https://doi.org/10.1002/prp2.757 |